In a recent regulatory development, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

It's not every day that Health and Human Services Secretary Robert F. Kennedy Jr. and Independent Senators Bernie Sanders and Angus King would agree on, well, anything. But when it comes to the ...

The offering, the first IPO this year, attracted more than 32 billion dirhams ($3.5 bln) in demand for 500 million dirhams in shares. GSK seeks FDA nod for expanded use of RSV vaccine in adults ...

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug Blenrep, when used in combination with other treatments, may cause eye damage in ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.

Deutsche Bank analyst Emmanuel Papadakis reiterated a Hold rating on GlaxoSmithKline today and set a price target of p1,450.00. The company’s shares opened today at p1,392.00. D ...

Mumbai: GlaxoSmithKline Pharmaceuticals Limited has announced the appointment of Vishwanath Swarup as Commercial Head - ...

Glaxosmithkline, with multiple operations in Montco, just scored a major regulatory win that could reshape how lupus ...